Congress file hr3029-119, before Congress. Still to be decided as of 2026-07-20.
Latest action: Motion to reconsider laid on the table Agreed to without objection.
Labs get federal guidelines for DNA safety NIST will create standards that tell labs how to safely screen custom DNA and RNA orders before making them.
Drug and farming companies get security rules Biotech companies making medicine and agricultural products will follow new safety standards when ordering or creating synthetic genetic material.
Small labs may struggle to meet new rules Smaller research facilities and startups could face higher costs to adopt new safety standards, and the standards may take years to finalize.
This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)In carrying
Read the official record for hr3029-119
See everything up for a vote · This week in Congress · See what we have filed with the clerk